Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma

NCT01673737 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01673737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01673737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2012
Completion date
February 28, 2015
Enrollment
75 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm malignant